MedWatch Digest: A warning for patients with diabetes who rely on insulin — and more
For Monday, March 25, WGN’s Patrick Elwood and Jenna Barnes have the latest on new medical information including:
More Coverage: WGN’s Medical Watch
The body’s own cells treat cancer
The FDA has approved tumor-infiltrating lymphocyte or Til therapy for treating the most dangerous type of skin cancer. Til therapy works by extracting T-cells from the patient.
Those are grown into billions of cancer-blasting immune cells in a lab, then infused back into the patient.
Now, researchers at the Ohio State University Comprehensive Cancer Center want to expand the benefits of Til therapy to other aggressive cancers.
In a clinical trial, it’s shown promise in advanced lung cancers.
Ohio State researchers are currently conducting other clinical trials to use Til therapy to treat gastrointestinal cancers and sarcoma.
Eli Lilly warns of temporary insulin shortage
Drug maker Eli Lilly is warning patients that two of its insulin formulations are temporarily out of stock.
The company says the ten-milliliter vials of Humalog and Insulin Lispro Injection will be in short supply at pharmacies through April.
It blames the shortage on a “brief delay in manufacturing,” but did not elaborate.
However, pre-filled pen versions of those medicines are still available.
Eli Lilly promises to ship out the ten-milliliter vials as soon as possible.
Sign up for our Medical Watch newsletter. This daily update includes important information from WGN’s Dina Bair and the Med Watch team including the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments as well as personal features related to people in the medical field. Sign up here.
For the latest news, weather, sports, and streaming video, head to WGN-TV.
